Blood protein levels could predict immunotherapy success in common cancers
NCT ID NCT07485114
First seen Mar 28, 2026 · Last updated May 23, 2026 · Updated 7 times
Summary
This observational study is exploring whether levels of a protein called Galectin-3 in the blood are linked to how well patients with kidney, lung, bladder, or liver cancer respond to immunotherapy drugs (PD-1/PDL-1 inhibitors). Researchers will measure Galectin-3 before each treatment and track outcomes like tumor response, survival, and side effects. The goal is to see if this protein can help predict treatment success or guide future therapies. The study plans to enroll 300 adults starting immunotherapy for the first time.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Tel Aviv Sourasky Medical Center
RECRUITINGTel Aviv, Israel, 64239, Israel
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.